Early results from Wave's ongoing DMD Phase II trial saw a decline in muscle necrosis and inflammation in the trial ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for ...

Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics ...

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an increase over baseline at 12 months.

Patients with Duchenne muscular dystrophy (DMD) have seen an “unprecedented and sustained” functional improvement in a Phase I/II trial examining Dyne Therapeutics’ DYNE-251. Announced as ...

Dyne Therapeutics (NASDAQ:DYN) on Monday  reported new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating “unprecedented and sustained functional improvement at ...

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

Announced as part of the 2025 Muscular Dystrophy Association (MDA) annual meeting, the ongoing Phase 1/2 Deliver trial investigated the company’s intravenous therapy specifically in patients who are ...

New York, NY, March 16, 2025 (GLOBE NEWSWIRE) -- In a bold move to promote equity and economic empowerment in New York's legal cannabis market, Silly Nice, a Black and Veteran-owned cannabis brand, ...

Dyne Therapeutics (DYN) announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented ...